All Stories

  1. Cytokine storm in the pathophysiology of COVID-19: Possible functional disturbances of miRNAs

    Article • International Immunopharmacology, December 2021, Elsevier

    Seyed Shahabeddin Mortazavi-Jahromi

  2. Efficient roles of miR-146a in cellular and molecular mechanisms of neuroinflammatory disorders: An effectual review in neuroimmunology

    Article • Immunology Letters, October 2021, Elsevier

    Seyed Shahabeddin Mortazavi-Jahromi

  3. A comprehensive review on miR-146a molecular mechanisms in a wide spectrum of immune and non-immune inflammatory diseases

    Article • Immunology Letters, August 2020, Elsevier

    Seyed Shahabeddin Mortazavi-Jahromi

  4. Effects of mannuronic acid (M2000) on gene expression profile of signal transducer and activator of transcription proteins (STATs) in rheumatoid arthritis patients

    Article • Reumatismo, July 2020, PAGEPress Publications

    Seyed Shahabeddin Mortazavi-Jahromi

  5. The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients

    Article • Recent Patents on Inflammation & Allergy Drug Discovery, March 2020, Bentham Science Publishers

    Abbas Mirshafiey, Seyed Shahabeddin Mortazavi-Jahromi

  6. The role of β-d-mannuronic acid, as a new non-steroidal anti-inflammatory drug on expression of miR-146a, IRAK1, TRAF6, NF-κB and pro-inflammatory cytokines following a clinical trial in rheumatoid arthritis patients

    Article • Immunopharmacology and Immunotoxicology, March 2020, Taylor & Francis

    Seyed Shahabeddin Mortazavi-Jahromi

  7. Anti-Diabetic and Angio-Protective Effect of Guluronic Acid (G2013) as a New Nonsteroidal Anti-Inflammatory Drug in the Experimental Model of Diabetes

    Article • Endocrine Metabolic & Immune Disorders - Drug Targets, March 2020, Bentham Science Publishers

    Seyed Shahabeddin Mortazavi-Jahromi, Shahab Alizadeh, Abbas Mirshafiey

  8. Immunopharmacological effect of β‐ d ‐mannuronic acid (M2000), as a new immunosuppressive drug, on gene expression of miR‐155 and its target molecules (SOCS1, SHIP1) in a clinical trial on rheumatoid arthritis patients

    Article • Drug Development Research, November 2019, Wiley

    Seyed Shahabeddin Mortazavi-Jahromi

  9. International multicenter randomized, placebo-controlled phase III clinical trial of β-d-mannuronic acid in rheumatoid arthritis patients

    Article • Inflammopharmacology, January 2019, Springer Science + Business Media

    Seyed Shahabeddin Mortazavi-Jahromi, Salvatore Cuzzocrea

  10. Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties

    Article • Immunologic Research, November 2018, Springer Science + Business Media

    Seyed Shahabeddin Mortazavi-Jahromi

  11. Modification of Sexual Hormones in Rheumatoid Arthritis Patients by M2000 (β-D-mannuronic Acid) as a Novel NSAID with Immunosuppressive Property

    Article • Endocrine Metabolic & Immune Disorders - Drug Targets, August 2018, Bentham Science Publishers

    Seyed Shahabeddin Mortazavi-Jahromi, Hossein Ahmadi, Abbas Mirshafiey, Maryam Monsef Shokri

  12. Anti-diabetic effect of β-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property on insulin production, blood glucose, and inflammatory markers in the experimental diabetes model

    Article • Archives of Physiology and Biochemistry, June 2018, Taylor & Francis

    Seyed Shahabeddin Mortazavi-Jahromi, Shahab Alizadeh

  13. Evaluation of the Effect of a-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property

    Article • Recent Patents on Inflammation & Allergy Drug Discovery, June 2018, Bentham Science Publishers

    Seyed Shahabeddin Mortazavi-Jahromi, Abbas Mirshafiey, Salvatore Cuzzocrea

  14. Effect of β-D-mannuronic acid (M2000) on oxidative stress enzymes’ gene using healthy donor peripheral blood mononuclear cells for evaluating the anti-aging property

    Article • Current Drug Discovery Technologies, May 2018, Bentham Science Publishers

    Seyed Shahabeddin Mortazavi-Jahromi

  15. A phase I/II randomized, controlled, clinical trial for assessment of the efficacy and safety of β-d-mannuronic acid in rheumatoid arthritis patients

    Article • Inflammopharmacology, April 2018, Springer Science + Business Media

    Seyed Shahabeddin Mortazavi-Jahromi, Salvatore Cuzzocrea

  16. Cardioprotective effect of β-d-mannuronic acid (M2000) as a novel NSAID on gene expression of oxLDL scavenger receptors in the experimental diabetic model

    Article • Immunopharmacology and Immunotoxicology, April 2018, Taylor & Francis

    Abbas Mirshafiey, Seyed Shahabeddin Mortazavi-Jahromi, Shahab Alizadeh

  17. Oral administration effects of β- d -mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis

    Article • Biomedicine & Pharmacotherapy, April 2018, Elsevier

    Seyed Shahabeddin Mortazavi-Jahromi, Salvatore Cuzzocrea

  18. Two Faces of LRBA Deficiency in Siblings: Hypogammaglobulinemia and Normal Immunoglobulin Levels

    Article • Journal of Investigational Allergology and Clinical Immunology, February 2018, Esmon Publicidad, SA

    Seyed Shahabeddin Mortazavi-Jahromi

  19. Anti-angiogenesis effect of β-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive properties under experimental model

    Article • Clinical and Experimental Pharmacology and Physiology, February 2018, Wiley

    Abbas Mirshafiey, Seyed Shahabeddin Mortazavi-Jahromi

  20. Effects of guluronic acid (G2013) on SHIP1, SOCS1 induction and related molecules in TLR4 signaling pathway

    Article • International Immunopharmacology, February 2018, Elsevier

    Seyed Shahabeddin Mortazavi-Jahromi

  21. The circulating T helper subsets and regulatory T cells in patients with common variable immunodeficiency with no known monogenic disease

    Article • Journal of Investigational Allergology and Clinical Immunology, January 2018, Esmon Publicidad, SA

    Seyed Shahabeddin Mortazavi-Jahromi

  22. Introduction of β- d -mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1/COX-2 activity and gene expression

    Article • Pharmacological Reports, October 2017, Elsevier

    Seyed Shahabeddin Mortazavi-Jahromi, Salvatore Cuzzocrea

  23. An in vitro evaluation of anti-aging effect of guluronic acid (G2013) based on enzymatic oxidative stress gene expression using healthy individuals PBMCs

    Article • Biomedicine & Pharmacotherapy, June 2017, Elsevier

    Seyed Shahabeddin Mortazavi-Jahromi

  24. Pharmacological effects of β- d -mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-κB gene expression, as target molecules in inflammatory reactions

    Article • Pharmacological Reports, June 2017, Elsevier

    Seyed Shahabeddin Mortazavi-Jahromi

  25. Inhibitory effect of G2013 molecule as a novel immunomodulatory agent, on miR-155 gene expression in HEK-Blue hTLR4 cell line

    Article • European Journal of Inflammation, July 2016, SAGE Publications

    Abbas Mirshafiey, Seyed Shahabeddin Mortazavi-Jahromi